Costly leukaemia pill wins UK green light after price cut

LONDON, Nov 25 (Reuters) - A costly blood cancer pill sold

in Europe by Johnson & Johnson will be made routinely

available to certain patients in Britain with chronic

lymphocytic leukaemia, after the U.S. company agreed to cut the

price.

Read more